anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For volunteers only, screening tests such as questionnaires, physical examinations, and clinical laboratory tests will be conducted within 4 weeks (-28d to -1d) from the date of clinical trial conduct to select test subjects deemed suitable for this clinical trial. Subjects determined to be suitable for this clinical trial are admitted to the Seoul National University Hospital Clinical Trial Center in the afternoon one day (-1d) before the first administration of the investigational drug and must fast for at least 10 hours. In the morning of Day 1, test subjects receive intravenous administration of the clinical trial drug for 30 minutes. Pharmacokinetics, immunogenicity and safety evaluations are conducted according to the planned schedule. Test subjects are hospitalized at the clinical trial center for 4 days (discharged on the 4th day), and after administration of the investigational drug, on 8d, 11d, 15d, 22d (±1d), and 29d (±2d), for pharmacokinetics, immunogenicity, and safety evaluation. Visit the clinical trial center. It proceeds sequentially starting from the lowest dose group, and whether to proceed to the next dose is decided based on the tolerability and safety results up to 15 days of the previous dose.
At each clinic, routine assessment of smoking status occurs at least annually for patients receiving care, but prescription for pharmacotherapy for smoking cessation and referral for behavioral smoking cessation services are rare. Patients will receive the standard of care at the clinic they attend. SOC patients will also attend the first session that participants in the other sessions receive (pre-randomization), will come to the clinic for assessment only during the weeks lining up with sessions 6-10 for the other conditions, and receive the transdermal nicotine patch for 8 weeks.
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by synovitis, bone and cartilage destruction, and increased fracture risk with bone loss. Although disease-modifying antirheumatic drugs have dramatically improved clinical outcomes, these therapies are not universally effective in all patients because of the heterogeneity of RA pathogenesis. Therefore, it is necessary to elucidate the molecular mechanisms underlying RA pathogenesis, including associated bone loss, in order to identify novel therapeutic targets. In this study, we found that Budding uninhibited by benzimidazoles 1 (BUB1) was highly expressed in RA patients' synovium and murine ankle tissue with arthritis. As CD45+CD11b+ myeloid cells are a Bub1 highly expressing population among synovial cells in mice, myeloid cell-specific Bub1 conditional knockout (Bub1ΔLysM) mice were generated. Bub1ΔLysM mice exhibited reduced femoral bone mineral density when compared with control (Ctrl) mice under K/BxN serum-transfer arthritis, with no significant differences in joint inflammation or bone erosion based on a semi-quantitative erosion score and histological analysis. Bone histomorphometry revealed that femoral bone mass of Bub1ΔLysM under arthritis was reduced by increased osteoclastic bone resorption. RNA-seq and subsequent Gene Set Enrichment Analysis demonstrated a significantly enriched nuclear factor-kappa B pathway among upregulated genes in receptor activator of nuclear factor kappa B ligand (RANKL)-stimulated bone marrow-derived macrophages (BMMs) obtained from Bub1ΔLysM mice. Indeed, osteoclastogenesis using BMMs derived from Bub1ΔLysM was enhanced by RANKL and tumor necrosis factor-α or RANKL and IL-1β treatment compared with Ctrl. Finally, osteoclastogenesis was increased by Bub1 inhibitor BAY1816032 treatment in BMMs derived from wildtype mice. These data suggest that Bub1 expressed in macrophages plays a protective role against inflammatory arthritis-associated bone loss through inhibition of inflammation-mediated osteoclastogenesis.
In treatment Arm A1 Period 1 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. In treatment Arm A1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
A therapeutic agent for a hormone-dependent cancer, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval, is provided. A method for treating a hormone-dependent cancer, which comprises administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval, is also provided. A steroid-sulfatase inhibitor which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval, is also provided. A kit for treating a hormone-dependent cancer, which comprises a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. A pharmaceutical composition, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. Further, use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy for the manufacture of a therapeutic agent for a hormone-dependent cancer is provided.
A computer-assisted and automatic identification of possible cranial positions for any kind of implant is presented. In this method, skull data of the individual patient's skull are used as well as statistical skull data which include so-called skull avoidance zones. Further, a digital template of the implant is used to find these possible positions. The implant may be e.g. an IPG and/or the screws of a fixation frame, but these are only embodiments of implants and other implants may be used with the present invention as well. The computer-implemented medical method of the present invention removes the uncertainty whether a given patient can safely receive an implant, like for example a cranial IPG, which was previously only possible on the basis of human judgement. Furthermore, the present invention removes the uncertainty whether a given patient can be safely fixated in a stereotactic frame or a Mayfield head clamp. The present invention supports the localization of optimal implant location as well as neuro-navigation guided execution of surgery. This enhances safety and speed of the entire medical procedure, as will be explained in more detail hereinafter. The advantages described hereinbefore are in the same way realized by the computer program, the medical system and the navigation system for computer-assisted surgery of the present invention.
The Pentacam Classic (Oculus Optikgerate GmbH, Heidelberg, Germany, software version 1.14r04) was used for the sake of the study.32 patients with keratoconus were included in the study. Of them, 19 patients underwent CxL treatment (CxL group), while the rest 13 patients underwent CxL combined with t-PRK (tCxL) \[tCxL group\]. If both eyes were eligible, only one eye was enrolled in the study.Regarding Scheimpflug camera (Pentacam Classic, Oculus Optikgerate GmbH, Heidelberg, Germany, software version 1.14r04 ) measurements, acceptable maps had at least 10.0mm of corneal coverage. Moreover, images with extrapolated data in the central 9.0mm zone were excluded.

For both anterior and posterior corneal surfaces, Pentacam-derived HOAs parameters for both pupil diameters of 4mm and 6mm were calculated, as well as the HOA root mean square (RMS)values. Pentacam-derived HOA measurements were obtained one day prior to treatment and then one year post-op.The impact of the surgical technique (either CXL or tCXL) on spherocylindrical error was evaluated by power vector analysis as described before. Furthermore, manifest refractions comprising of sphere (S), cylinder (C) and axis (φ), were converted into three dioptric powers (M, J0 and J45). Moreover, we calculated the overall blurring strength (B) of the spherocylindrical error by measuring the length of the produced vector.
The study data were collected by the researchers using online systems with the snowball method due to the pandemic. The inclusion criteria of the study (not having undergone abdominal surgery in the last three months, not having uncontrolled hypertension, not having glaucoma, hernia, epilepsy, not having received a psychiatric diagnosis-treatment, not having received a diagnosis-treatment for sleep problems, having done laughter yoga before) The study consisted of 100 nurses who agreed to participate in the study. Descriptive features form consisting of 13 questions, Connor-Davidson Resilience Scale (CD-RISC) scale and Pittsburgh Sleep Quality Index (PSQI) were used to collect data. Research data were collected in 3 months. During the study, 4 people from the experimental group (3 people did not attend the sessions regularly, 1 person left voluntarily), 6 people from the control group (he left voluntarily) quit the study. Finally, the research was completed with 90 nurses, 46 of which were in the experimental group and 44 in the control group.
Cardiovascular disease (CVD) is an umbrella term that includes various pathologies involving the heart and the vasculature system of the body. CVD is the leading cause of death worldwide, accounting for an estimated 32% of all deaths. More than 40% of annual deaths in Jordan are due to CVD; this number is further expected to rise, particularly in the Eastern Mediterranean region where Jordan is located. Due to the chronic nature of CVD, the presence of a caregiver who can help mitigate the challenges patients face is essential, and their level of knowledge determines the quality of care they can provide. Hence, this cross-sectional study was conducted in the cardiology clinics at Jordan University Hospital (JUH). Questionnaires were distributed to 469 participants, defined in this study as the caregivers escorting patients with established coronary heart disease (CHD). The self-administered questionnaire included three sections: sociodemographic and health factors, knowledge of CVD risk factors, and CHD symptoms. The mean age of the study population was 44.38 years ± 15.92 and 54.2% of participants were males. Regarding knowledge of CVD risk factors, 84.6% of participants answered more than 70% of the questions correctly. More than 95% knew that chest pain is a symptom of an acute cardiovascular event. However, only 53.5% and 74.8% of the participants reported that jaw pain and arm pain are symptoms of an acute event, respectively. Several factors influenced the caregiver's knowledge, such as age, income, frequent health checkups, having a history of CVD, CKD, or DM, and their relationship to the patient. This study sheds light on the importance of caregiver knowledge in patient care. By improving the caregivers' knowledge, identifying their role in patient care, and raising CVD awareness in susceptible populations, healthcare professionals can improve the patients' quality of life. Overall, assessing caregivers' knowledge pertaining to CVD can provide invaluable data, which may enhance patient care by educating their caregivers.
BACKGROUND: Children requiring liver transplantation generally have severe growth retardation. Recipients experience posttransplantation catch-up growth, although some show short adult heights. We aimed to determine decades-long catch-up growth trends and risk factors for short adult height following liver transplantation.
METHODS: We analyzed long-term height Z scores and risk factors for short adult height in a single-center retrospective cohort of 117 pediatric liver transplantation recipients who survived >5 y, with 75 of them reaching adult height.
RESULTS: Median age at transplantation was 1.3 y, and the most common primary diagnosis was biliary atresia (76.9%). Mean height Z scores pretransplantation and 1, 3, and 8 y after transplantation were -2.26, -1.59, -0.91, and -0.59, respectively. The data then plateaued until 20 y posttransplantation when mean adult height Z score became -0.88, with a median follow-up of 18.6 y. Nineteen recipients did not show any catch-up growth, and one quarter of recipients had short adult height (<5th percentile of the healthy population). Multivariate analysis identified old age (odds ratio, 1.22 by 1 y; P = 0.002), low height Z scores at transplantation (odds ratio, 0.46 by 1 point; P < 0.001), and posttransplantation hospital stay ≥60 d (odds ratio, 4.95; P = 0.015) as risk factors for short adult height. In contrast, prolonged steroid use after transplantation was not considered a significant risk factor.
CONCLUSIONS: Although tremendous posttransplantation catch-up growth was observed, final adult height remained inadequate. For healthy physical growth, liver transplantation should be performed as early as possible, before growth retardation becomes severe.
Natural progesterone inhibits the proliferation of normal breast epithelial cells in vivo, as well as breast cancer cells in vitro. The anti-proliferative activity of natural progesterone in normal tissue is due to its ability to induce apoptosis. The genes P53 and bcl-2 genetically control the apoptic process and are involved in the natural progesterone induced apoptosis. Natural progesterone levels similar to levels seen during the third trimester of pregnancy exhibited a strong anti-proliferative effect on at least two breast cancer cell lines. Apoptosis was induced in the stronger progesterone receptor expressing T47-D cells. Exposure of T47-D breast cancer cells to natural progesterone significantly down regulated expression of bcl-2 and concomitantly up-regulated expression of p53, indicating both genes are involved in natural progestorone-induced apoptosis. A composition containing exogenous natural progesterone formulated for topical application is disclosed which may be used to establish and maintain a plasma concentration of natural progesterone of greater than 10 nanograms per ml which level is sufficient to destroy breast cancer cells.
Background: AF is a heterogeneous arrhythmia. At its simplest, it is triggered by rapidly firing foci around pulmonary veins (PV) and can be cured by isolation of PV alone. Evidences suggest that when high frequency of atrial activation is maintained for relatively longer period (as in persistent or long-standing AF), ion channel remodeling changes the electrophysiologic substrate and lead to AF permanence. Therefore, PVAI alone, as anticipated, demonstrates to have limited success rate in persistent and LSP AF and additional ablations beyond PVAI involving substrate modification are advocated by many experts in electrophysiology. However, there is yet no consensus on the ablation strategy for long-standing AF. It is still not clear whether AF termination during ablation could be considered as an ablation endpoint or not, as earlier studies have reported results that are at variance with each other. Some studies have suggested that termination of AF during ablation is associated with reduced recurrence of arrhythmia while others detected no association of AF termination with long-term maintenance of sinus rhythm (SR) in persistent or LSP-AF.Therefore this study aims to examine ablation outcomes in LSP-AF patients with AF termination with or without additional ablation of extra-PV triggers.

Hypothesis: AF termination does not eliminate the need for additional ablations in achieving long-term ablation success in LSP-AF.
In the GameSAE group, participants will attend a tailor-made game-based exercise training program. Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week.
The invention relates to a hair restorer, specifically a hair restorer containing stem cells and a preparation method thereof, and belongs to the technical field of hair washing products. The materials of the hair restorer are divided into two groups, a group A and a group B. The group A comprises, by weight, cetanol 2%, stearic acid 2%, glycerol monostearate 1%, vaseline 2%, lanolin 10%, vitamin E 0.2% and propolis 0.5%, and the group B comprises, by weight, stem cell extract 10%, granulesten 1%, protolysate 2%, glycerinum 5%, lactic acid 0.5%, aseptic 1% and the balance deionized water. The preparation method comprises mixing the materials of group A, heating the mixture to 70 DEG C to 75 DEG C, heating the deionized water to 70 DEG C to 75 DEG C, adding the materials of group A into the deionized water, mixing the mixture uniformly, stirring and cooling the mixture, adding the materials of group B to the mixture when the temperature drops below 40 DEG C, and mixing the mixture uniformly. The hair restorer containing stem cells provided by the invention can enter hair follicles after being absorbed by scalp to overcome the problem of alopecia. Moreover, the hair keratin is differentiated, the aged protein is updated and replaced rapidly, synthetic activity of the protein is improved, and elasticity and softness of the hair are improved.
Children will be assigned to either the familiar or less-familiar word group. All children will receive 8 weeks of Vocabulary Acquisition and Usage for Late Talkers (VAULT) word learning treatment (2x/wk for 30 minutes each session). The investigators will measure how well children learn the words they are taught as well as the words that are in the environment, but not explicitly taught (control words). This will help us know if their learning is due to treatment or maturation. The investigators will compare children to themselves (taught words v. control words) to ensure that the overall treatment is working. Then, the investigators will compare children in the familiar word group to children in the less-familiar word group to see which group learns more overall.
Medical chart database to identify patients ,of one thoracic surgeon over the last seven years, who underwent thoracic resection and were discharged home with an air leak and chest tube to portable drainage device was completed. Once all patients were identified, all possible vulnerable patients were discarded. Written consent for participation was obtained by eligible patients and subjects willing to participate were given further explanation of the study. All willing participants completed an Outpatient Chest Tube Quality of Life Questionnaire. Upon completion of the questionnaire participants involvement in the study was complete. Data was collected and correlations between variables statistically analysed to determine significant factors affecting care.
When administered intravenously, fosaprepitant, a prodrug of aprepitant, is converted to aprepitant within 30 minutes. Therefore, drug interactions following administration of fosaprepitant for injection are likely to occur with drugs that interact with oral aprepitant.

Fosaprepitant, given as a single 150-mg dose, is a weak inhibitor of CYP3A4, and the weak inhibition of CYP3A4 continues for 2 days after single dose administration. Single dose fosaprepitant does not induce CYP3A4. Aprepitant is a substrate, an inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9 [see Clinical Pharmacology (12.3)].

Some substrates of CYP3A4 are contraindicated with fosaprepitant [see Contraindications (4)]. Dosage adjustment of some CYP3A4 and CYP2C9 substrates may be warranted, as shown in Table 7.
Tolerogenic populations of dendritic cells are provided, where the dendritic cells are characterized by expression of select tissue-specific homing receptors including the chemokine receptors CCR9; or CMKLR1; or the integrin CD103. The dendritic cells may be conventional/myeloid or plasmacytoid dendritic cells. The cells may be isolated from lymphoid tissue, from blood, or from in vitro culture, e.g. bone marrow culture, etc. Methods are provided for their identification, isolation and targeting in immunotherapeutic interventions in suppressing inflammatory disorders including autoimmunity, transplantation responses and allergic diseases. In some embodiments dendritic cell populations are fixed to render them immunosuppressive, thus allowing the cells to be typed and banked for future use.
Methods: Sixty participants with no history of neck pain or trauma were randomized into one of two groups: stretching group (n = 30), or control group (n = 30). The stretching group received a standardized manual stretching protocol. The control group did not received intervention. Pre and Post-test measurements were recorded for both groups. Within group differences and group by time interactions were evaluated for Cervical range of motion ROM and myofascial sensitivity. The immediate improvement in active ROM of the cervical spine may prompt clinicians to consider the sequencing of treatment. Stretching prior to active exercises may allow for active exercise through a larger ROM. Future research is needed to evaluate the immediate effects of stretching in the symptomatic population.
Modified enzymes are prepared for use in skin care products by covalently coupling to the enzymes from 4 to 70 polymeric molecules with or without a linker such as a triazine ring. Molecular weight of the polymeric molecules may be from 1 to 35 kDa and of the enzymes from 15 to 100 kDa. The number and weight of polymeric molecules coupled is balanced with the weight and/or surface area of the enzymes. Enzymes include proteases such as subtilisins, lipases and oxidoreductases such as laccases and superoxide dismutase, and polymeric molecules include polysaccharides such as dextran or pullulan and polyalkylene oxides such as polyethylene glycol. The polymeric molecules may be coupled to the enzymes at the N-terminal amino group and/or lysine residues, and preferably at a position more than 5 Å from the active site of the enzymes. A preferred modified enzyme is a protease having from 5 to 13 coupled polymeric molecules. Skin care products containing the modified enzymes have improved stability and reduced allergenicity as compared to the products containing the unmodified enzymes.
The invention relates to a ventilating device for a ridge coping, preferably for a top ridge of a roof. The ventilating device comprises a ridge member consisting of two opposed panels between which cross pieces are established. Passages for humid air from a roof construction to the ambient atmosphere is established either between the cross pieces or in the cross pieces. The passages pass from a lower part of the ridge member to an upmost part of the ridge member. Preferably, the ventilating device is provided with flexible parts extending from the lower part of the ridge member and downwards and outwards. The flexible parts are intended for abutting an underroof. Different types of mounting means for mounting of ridge tiles to the ventilating device is also comprised. The ventilating device according to the invention makes ventilation of roof constructions through a ridge coping much easier and much more flexible.